Conceived and designed the experiments: RH NP LP. Performed the experiments: NP LP CW. Analyzed the data: LP. Contributed reagents/materials/analysis tools: RH LP. Wrote the paper: RH NP LP.
Hox genes are implicated in hematopoietic stem cell (HSC) regulation as well as in leukemia development through translocation with the nucleoporin gene
These findings provided a potentially powerful approach to identify key pathways mediating Hox-induced expansion and transformation of HSCs by identifying gene expression changes commonly induced by ND13 and NA10 but not by a NUP98-Hox fusion with a non-DNA binding homedomain mutation (N51S). The gene expression repertoire of purified murine bone marrow Sca-1+Lin- cells transduced with retroviral vectors encoding for these genes was established using the Affymetrix GeneChip MOE430A. Approximately seventy genes were differentially expressed in ND13 and NA10 cells that were significantly changed by both compared to the ND13(N51S) mutant. Intriguingly, several of these potential Hox target genes have been implicated in HSC expansion and self-renewal, including the tyrosine kinase receptor
In conclusion this study has identified several novel Hox downstream target genes and provides important new leads to key regulators of the expansion and transformation of hematopoietic stem cells by Hox.
The 39 clustered Hox proteins are an evolutionary preserved family characterized by a 60 amino acid DNA-binding motif called the homeodomain.
The mechanisms by which Hox proteins mediate their effects and how they perturb cellular functions are not well understood. They seem to be highly context dependent in their actions
The relatively long latency of Hox-induced AML in mouse models strongly indicates that additional genetic events are required for full leukemic progression
In an effort to gain insight into the nature of the possible genetic programs impacted by Hox relevant to stem cell self-renewal and leukemogenesis we have used microarray technology to assess gene expression perturbations induced by NUP98-HOX fusions 24 hours post transduction into murine primary bone marrow Sca-1+Lin- cells enriched in HSC and progenitors cells. We compared two NUP98-HOX fusions (NA10 and ND13) with a non DNA-binding and non-transforming ND13(N51S) homeodomain mutant. Surprisingly, a relatively small number of genes were significantly differentially expressed in cells harboring the ND13 or NA10 fusions compared to control cells and several potential target genes implicated in HSC expansion and self-renewal were identified with this approach.
The NUP98-HOXA10 and NUP98-HOXD13 fusion gene as well as the N51S-ND13 dead homeodomain mutant gene constructs have been described elsewhere
Mice were bred and maintained at the British Columbia Cancer Research Centre animal facility. Donors of primary BM cells were older than 12-weeks (C57Bl/6Ly-Pep3b×C3H/HeJ) F1 (PepC3) mice. Primary mouse BM cells were transduced as previously described
The single cell suspensions collected were blocked for 10 min on ice with 5 µg/ml anti mouse CD16/CD32 (Fc Block, BD Pharmingen) in Phosphate Buffered Saline (STI)+2% Fetal Bovine Serum (PF). Cells were washed once with PF and then incubated on ice for 20 min with the primary mAb. Cells were then washed once, incubated with the secondary antibody if needed, washed again, and then analysed by flow cytometry using a FACSCalibur™ flow cytometer and CELLQuest™ software (BD Pharmingen). GFP+ Sca-1+Lin- cells were sorted using a FACSVantage™ (BD Pharmingen). Purity>90% were confirmed by re-analysis of sorted cells. The forward versus side scatter profile was used to gate on viable cells and an unstained sample was used to determine appropriate gating for expression. Monoclonal antibodies (mAbs) were all purchased from PharMingen (San Diego, CA) (phycoerythrin [PE]–labeled Gr-1, B220, Ter-119, CD4, CD5 and CD8).
Sorted cells were lyzed in Trizol™ (Invitrogen) and total RNA was extracted according to the manufacturer instructions. One hundred ng of total RNA from each sample were then double linear amplified with the ENZO BioArray High Yield RNA Transcript Labeling kit and the GeneChip Eukaryotic Small Sample Target Labeling Assay, Version II protocol (Affymetrix, Santa Clara, CA) to produce target for hybridization to Affymetrix MOE430 according to the manufacturer's instructions and performed at the Genome Science Centre, BC Cancer Agency, Vancouver, Canada. All experiments were performed in biological triplicate.
Gene array data (CEL-files) were imported into GeneSpring® software version 7.3 (Silicon Genetics, Redwood City, CA). The GC-RMA method
Non-amplified RNA from the transduced murine primary bone marrow samples was used for validation with quantitative RT-PCR (qRT-PCR). RNA was isolated using Trizol™ and the samples were then treated with DNase I (amplification grade, Invitrogen). Complementary DNA (cDNA) was generated by reverse transcription (RT) with the iScript cDNA Synthesis Kit (BioRad Inc., Hercules, CA). Gene transcripts were quantified by real-time PCR using the iCycler apparatus (Bio-Rad Inc., Hercules, CA) and were detected with SYBR Green as flurochrome (IQ™ SYBR® Green Supermix, BioRad Inc.). Gene sequences for primer design were obtained from the NCBI Reference Sequences database (
The part of the study involving patient samples and healthy volunteers was performed in accordance to the Declaration of Helsinki and with approval by the local ethics committee at Göteborg University and informed written consent was obtained from all participants. All samples were collected at diagnosis between year 2000 and 2006 and stored at the department of Clinical Chemistry and Transfusion Medicine at Sahlgrenska University Hospital. The analysis included 34 adult patients, 20 females and 14 males, with de novo AML, representing FAB subclasses M0-M5. Mean age at diagnosis was 56 year (range 26 to 83). Four healthy volunteers were donors of normal bone marrow that was pooled for assay normalization.
RNA from patient and healthy volunteer samples was isolated using Trizol™ (Invitrogen, Cat.No. 15596-026). Complementary DNA (cDNA) was generated from 500 ng RNA by reverse transcription (RT) with random primers and the Superscript II enzyme and RNase inhibitor (Invitrogen) in a reaction volume of 20 µL. The RT reaction was incubated at 42°C for 50 minutes followed by 15 minutes at 70°C. Before the enzymes were added the mix was preheated at 65°C for 10 minutes. All assays were performed on an ABI Prism 7900 HT real-time PCR-system with ABI SDS Software 2.2.3 (Applied Biosystems, Foster City, CA, USA). For the TLDA 20 µL of cDNA, corresponding to 25 ng starting RNA, was mixed with 30 µL water and 50 µL TaqMan Universal PCR Master Mix (Applied Biosystems, Stockholm, Sweden); 100 µL was loaded per port. Thermal cycling conditions were 50°C for 2 minutes, 94.5°C for 10 minutes, 97°C for 30 seconds and 59.7°C for 1 minute. The relative expression changes were determined with the 2−ΔΔCT method
Microsoft® Excel in combination with the Excel plug-in software Analyse-It® v1.73 was used for the statistical calculations. Pearson regression was used for comparison between gene array and qRT-PCR results. Spearman rank correlation was used to test possible associations. Non-parametric Kruskal-Wallis 1-way ANOVA were used to evaluate differences between groups.
Adult murine bone marrow cells transduced with vectors carrying ND13, NA10, ND13(N51S) or an empty GFP control vector were isolated on the basis of GFP expression by FACS 24 hours post-transduction. Viable transduced cells were further enriched for primitive hematopoietic cells by exclusion of cells expressing linage markers (Gr-1, B220, Ter-119, CD4, CD5 and CD8) and selection for cells expressing the stem cell antigen-1 (Sca-1). This resulted in an overall recovery of 0.25–6% of all cells with a purity of 90–95% for GFP expression. The cells were kept on ice during sorting and immediately lyzed in Trizol for RNA extraction. Three independent experiments were performed for each of the four different conditions included in the study.
After extraction, RNA was amplified and analyzed using the Affymetrix GeneChip MOE430A array containing 23,000 probe sets. The Gene Chip robust multi-array analysis (GC-RMA) was used for initial normalization and the GFP control was used for per gene normalization. Pearson correlation coefficient between the experimental replicates ranged between r = 0.92–0.99 suggesting low inter-experimental variation and the 3′-to-5′ ratios for Gapdh and Actin in all samples were less than 3.0 (ranging from 1.7–2.7), indicating that no serious bias was introduced by the RNA amplification procedure. Our main interest was to define the subset of genes that could explain the transforming and cell expansion potential of NUP98-HOX fusions in the Sca-1+, GFP+, Lin- cell population and that also could be direct NUP98-Hox binding target genes. First, all genes that were significantly differentially expressed between ND13, NA10 or the presumably non DNA-binding ND13(N51S) and the GFP control were identified. Genes were considered differentially expressed if they had a change in expression level compared to control of at least 50% and the extent of difference in expression was statistically significant (p<0.05) in a parametric Welsh-ANOVA t-test. More genes were activated than repressed by all NUP98-HOX fusions, 560 activated and 43 repressed genes with ND13, 414 activated and 20 repressed genes with NA10 and 204 activated and 82 repressed genes with ND13(N51S), (
| Gene name and description | Accession # | ND13 fold change | ANOVA p-value | NA10 fold change | ANOVA p-value | Biological process |
| Crisp1, cysteine-rich secretory protein 1 | NM_009638 | 18.3 | 6.04E-06 | 30.8 | 7.92E-06 | Unknown |
| Nr4a1, nuclear receptor subfamily 4, group A, member 1 | NM_010444 | 8.1 | 2.90E-02 | 1.8 | 5.70E-03 | Transcription |
| Igh-6, immunoglobulin heavy chain 6 (heavy chain of IgM) | BB226392 | 5.0 | 2.90E-03 | 3.2 | 3.81E-05 | Signal transduction/Immune response/Cell proliferation |
| Ptprf, protein tyrosine phosphatase, receptor type, F | BF235516 | 4.5 | 3.69E-03 | 1.8 | 1.10E-03 | Signal transduction |
| Pdcd1lg2, programmed cell death 1 ligand 2 | NM_021396 | 4.1 | 3.79E-05 | 2.0 | 2.42E-03 | Cell proliferation |
| Pbx3, pre B-cell leukemia transcription factor 3 | NM_016768 | 3.9 | 6.23E-06 | 4.8 | 1.19E-05 | Transcription/Development |
| Hlf, hepatic leukemia factor | NM_172563 | 3.4 | 3.52E-02 | 6.8 | 4.03E-04 | Transcription/Cell proliferation |
| Ahr, aryl-hydrocarbon receptor | NM_013464 | 3.4 | 2.54E-03 | 3.1 | 2.35E-05 | Transcription/Signal transduction |
| Hlx1, H2.0-like homeo box 1 | NM_008250 | 3.4 | 3.99E-03 | 1.8 | 4.96E-03 | Transcription |
| Ier3, immediate early response 3 | NM_133662 | 3.3 | 9.35E-04 | 1.5 | 8.00E-03 | Unknown |
| Erbb2ip, Erbb2 interacting protein | BM240030 | 3.3 | 9.17E-04 | 2.3 | 1.21E-03 | Signal transduction |
| Tmem71, transmembrane protein 71 | AV173260 | 3.0 | 4.03E-05 | 2.5 | 4.65E-05 | Unknown |
| Pkp2, plakophilin 2 | AA516617 | 3.0 | 7.13E-06 | 1.7 | 1.48E-03 | Cell adhesion/Development |
| Pira1, paired-Ig-like receptor A1 | NM_011093 | 3.0 | 1.56E-02 | 2.3 | 2.13E-02 | Cell cycle/Immune response |
| Tgm2, transglutaminase 2, C polypeptide | BB041811 | 2.9 | 2.99E-03 | 2.9 | 3.04E-03 | Signal transduction/Metabolism/Cell adhesion |
| Lilrb3, leukocyte immunoglobulin-like receptor, subfamily B, member 3 | U96693 | 2.8 | 5.50E-03 | 2.0 | 8.22E-04 | Cell cycle/Immune response |
| Cables1, Cdk5 and Abl enzyme substrate 1 | AF328140 | 2.8 | 2.87E-03 | 1.8 | 2.59E-02 | Cell cycle/Development |
| H2-DMa, histocompatibility 2, class II, locus DMa | NM_010386 | 2.8 | 7.61E-03 | 2.2 | 1.74E-02 | Immune response/Transport |
| Ahrr, aryl-hydrocarbon receptor repressor | NM_009644 | 2.7 | 9.31E-04 | 2.2 | 2.48E-03 | Signal transduction/Transcription/Metabolism |
| Fads3, fatty acid desaturase 3 | BE652876 | 2.7 | 1.07E-02 | 1.9 | 7.20E-03 | Metabolism |
| Tspan6, tetraspanin 6 | NM_019656 | 2.7 | 1.14E-04 | 1.7 | 2.10E-03 | Unknown |
| Tmem51, transmembrane protein 51 | BC003277 | 2.7 | 5.61E-03 | 2.1 | 3.87E-03 | Unknown |
| Rab4a, RAB4A, member RAS oncogene family | NM_009003 | 2.6 | 1.41E-03 | 3.4 | 1.40E-04 | Transport/Signal transduction |
| Anxa1, annexin A1 | NM_010730 | 2.5 | 3.65E-03 | 2.4 | 4.42E-03 | Cell cycle/Cell proliferation/Signal transduction |
| Pscdbp, pleckstrin homology, Sec7 and coiled-coil domains, binding protein | BC007144 | 2.4 | 3.04E-03 | 1.6 | 4.34E-02 | Cell adhesion |
| F2rl2, coagulation factor II (thrombin) receptor-like 2 | NM_010170 | 2.4 | 8.34E-04 | 2.2 | 9.01E-04 | Coagulation/Signal transduction |
| RIKEN cDNA C230093N12 gene | BC023470 | 2.4 | 2.04E-03 | 1.5 | 1.70E-02 | Unknown |
| Cish, cytokine inducible SH2-containing protein | NM_009895 | 2.4 | 6.78E-04 | 1.6 | 3.19E-02 | Cell growth/Signal transduction |
| Tsc22d1, TSC22 domain family, member 1 | BB357514 | 2.4 | 2.60E-03 | 2.0 | 7.37E-03 | Transcription |
| Wdfy2, WD repeat and FYVE domain containing 2 | BB794924 | 2.4 | 6.33E-03 | 1.7 | 6.51E-03 | Unknown |
| Pld3, phospholipase D family, member 3 | NM_011116 | 2.3 | 8.47E-03 | 2.6 | 4.39E-05 | Metabolism |
| Dnase1l1, deoxyribonuclease 1-like 1 | AK009174 | 2.3 | 1.84E-02 | 1.9 | 2.87E-02 | Metabolism |
| Mylc2pl, myosin light chain 2, precursor lymphocyte-specific | NM_021611 | 2.3 | 2.35E-02 | 2.9 | 1.82E-03 | Unknown |
| RIKEN cDNA 1700027N10 gene | BC019423 | 2.3 | 4.46E-04 | 2.2 | 8.76E-04 | Unknown |
| Cyp4f16, cytochrome P450, family 4, subfamily f, polypeptide 16 | NM_024442 | 2.3 | 5.32E-04 | 1.9 | 2.91E-03 | Transport |
| Hoxa5, homeo box A5 | BC011063 | 2.3 | 7.95E-04 | 3.9 | 3.02E-05 | Transcription/Development |
| Crisp3, cysteine-rich secretory protein 3 | NM_009639 | 2.2 | 1.20E-04 | 2.1 | 3.50E-02 | Unknown |
| Procr, protein C receptor, endothelial | NM_011171 | 2.2 | 8.99E-03 | 2.5 | 5.25E-05 | Coagulation |
| Plek, pleckstrin | AF181829 | 2.2 | 5.53E-03 | 1.8 | 1.44E-02 | Signal transduction |
| Mitf, microphthalmia-associated transcription factor | BB763517 | 2.2 | 9.81E-03 | 1.9 | 2.58E-03 | Development/Transcription |
| Metrnl, meteorin, glial cell differentiation regulator-like | BC024445 | 2.1 | 2.00E-02 | 2.2 | 1.79E-02 | Unknown |
| Prnp, prion protein | BE630020 | 2.1 | 2.13E-03 | 2.3 | 8.29E-03 | Metabolism |
| Sord, sorbitol dehydrogenase | AV253518 | 2.1 | 1.49E-02 | 2.3 | 5.31E-04 | Unknown |
| Rpgrip1, retinitis pigmentosa GTPase regulator interacting protein 1 | AK015037 | 2.1 | 1.98E-04 | 1.6 | 3.35E-03 | Development |
| Gsn, gelsolin | NM_010354 | 2.1 | 8.22E-03 | 2.1 | 2.22E-02 | Transport |
| Hoxa7, homeo box A7 | NM_010455 | 2.0 | 2.45E-02 | 1.7 | 2.38E-02 | Transcription/Development |
| Mef2c, myocyte enhancer factor 2C | AI595932 | 2.0 | 2.58E-02 | 1.7 | 6.06E-03 | Transcription/Development |
| Eltd1, EGF, latrophilin seven transmembrane domain containing 1 | BC017134 | 2.0 | 2.94E-04 | 1.9 | 4.89E-04 | Signal transduction |
| Flt3, FMS-like tyrosine kinase 3 | NM_010229 | 2.0 | 2.44E-02 | 2.0 | 2.32E-02 | Signal transduction/Development |
| Ncoa1, nuclear receptor coactivator 1 | NM_010881 | 1.9 | 2.24E-02 | 1.5 | 6.81E-03 | Transcription/Signal transduction |
| Ddx4, DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 | AK014844 | 1.9 | 2.04E-03 | 13.3 | 1.92E-06 | Development |
| Calcrl, calcitonin receptor-like | AF209905 | 1.9 | 1.37E-02 | 1.8 | 1.97E-02 | Cell proliferation/Signal transduction/Development |
| St8sia4, ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 | NM_009183 | 1.9 | 1.87E-03 | 2.0 | 1.77E-03 | Metabolism |
| Glul, glutamate-ammonia ligase | AI391218 | 1.9 | 1.09E-02 | 1.7 | 1.64E-02 | Metabolism |
| Lrp10, low-density lipoprotein receptor-related protein 10 | BC011058 | 1.9 | 3.27E-03 | 1.8 | 5.96E-03 | Metabolism/Transport |
| Hoxa9, homeo box A9 | NM_010456 | 1.8 | 1.06E-02 | 2.5 | 1.33E-03 | Transcription/Development |
| Malat1, metastasis associated lung adenocarcinoma transcript 1 | AW012617 | 1.8 | 3.31E-02 | 1.9 | 1.27E-03 | Unknown |
| Ptk2b, PTK2 protein tyrosine kinase 2 beta | AV026976 | 1.8 | 8.99E-03 | 1.7 | 1.34E-02 | Signal transduction |
| Igfbp7, insulin-like growth factor binding protein 7 | AI481026 | 1.8 | 1.25E-02 | 1.7 | 2.41E-02 | Cell growth/Metabolism |
| Mxd4, Max dimerization protein 4 | BG868949 | 1.8 | 1.23E-02 | 1.8 | 7.84E-03 | Transcription |
| Sesn1, sestrin 1 | BG076140 | 1.8 | 1.60E-03 | 1.8 | 1.42E-03 | Cell cycle |
| Itm2c, integral membrane protein 2C | NM_022417 | 1.8 | 3.67E-03 | 1.5 | 2.97E-02 | Unknown |
| RIKEN cDNA 4930504E06 gene | BB010153 | 1.7 | 2.71E-02 | 1.8 | 2.82E-03 | Unknown |
| Man1a, mannosidase 1, alpha | NM_008548 | 1.7 | 9.38E-03 | 1.6 | 1.53E-02 | Metabolism |
| Aldoc, aldolase 3, C isoform | BC008184 | 1.7 | 2.36E-02 | 1.8 | 2.93E-02 | Metabolism |
| Cln3, ceroid lipofuscinosis, neuronal 3, juvenile | NM_009907 | 1.7 | 4.55E-03 | 1.7 | 5.18E-03 | Unknown |
| Arrb1, arrestin, beta 1 | AK004614 | 1.7 | 6.77E-03 | 1.8 | 7.22E-03 | Signal transduction |
| Cast, calpastatin | AB026997 | 1.7 | 8.19E-03 | 1.8 | 2.99E-03 | Metabolism |
| Nupr1, nuclear protein 1 | NM_019738 | 1.7 | 4.92E-03 | 2.0 | 8.18E-03 | Unknown |
| Jag2, jagged 2 | AV264681 | 1.7 | 2.21E-02 | 1.6 | 1.15E-02 | Signal transduction/Development/Cell proliferation |
| Bckdha, branched chain ketoacid dehydrogenase E1, alpha polypeptide | NM_007533 | 1.6 | 3.33E-02 | 1.8 | 1.30E-02 | Metabolism/Transcription |
| Prkcn, protein kinase C, nu | BF160591 | 1.6 | 1.17E-02 | 1.7 | 3.48E-03 | Signal transduction |
| Pnp, purine-nucleoside phosphorylase | AK008143 | 1.5 | 3.02E-03 | 1.5 | 2.90E-02 | Metabolism |
| Tcf4, transcription factor 4 | AI639846 | 1.5 | 2.96E-02 | 1.5 | 1.42E-02 | Transcription/Development |
To confirm the fidelity of the microarray data a subset of 15 genes was selected for validation using quantitative RT-PCR (
|
|
|
|
|
|
|
|
|
|
1.7 | 1.1 | 2.6 | 1.3 | 0.9 | 1.1 |
|
|
0.9 | 1.3 | 1.1 | 1.1 | 0.6 | 1.0 |
|
|
5.4 | 5.0 | 4.2 | 4.9 | 0.4 | 0.8 |
|
|
7.5 | 3.2 | 7.7 | 2.1 | 1.7 | 0.9 |
|
|
1.7 | 2.1 | 3.0 | 2.8 | 0.5 | 0.2 |
|
|
2.4 | 1.6 | 2.9 | 1.2 | 0.8 | 1.0 |
|
|
2.9 | 2.5 | 1.5 | 1.4 | 0.8 | 1.1 |
|
|
1.6 | 1.1 | 1.7 | 0.9 | 1.4 | 1.2 |
|
|
5.8 | 2.2 | 10.1 | 2.3 | 2.1 | 1.1 |
|
|
28.1 | 4.2 | 8.6 | 2.9 | 3.8 | 1.4 |
|
|
3.6 | 2.0 | 4.9 | 2.2 | 1.0 | 1.3 |
|
|
2.2 | 1.8 | 5.6 | 2.2 | 1.7 | 1.1 |
|
|
1.1 | 1.5 | 5.3 | 3.4 | 1.1 | 3.4 |
|
|
4.9 | 2.4 | 5.6 | 4.9 | 1.6 | 2.2 |
|
|
24.5 | 10.8 | 100.5 | 27.2 | 2.7 | 2.4 |
Fold changes are calculated against an empty MIG control and
The 74 genes that were both induced by ND13 and NA10 and whose expression was dependent on an intact homedomain were classified into gene ontology categories according to involvement in different biological processes. The genes were separated into 12 main categories (
Genes that were differentially expressed by both ND13 and NA10 but not the mutant ND13(N51S) mutant were classified according to involvement in different biological processes. Some genes are classified in more than one category resulting in the total number of genes indicated in the figures being greater than the total number of differentially expressed genes.
Several of the genes induced by ND13 and NA10 were Hox or Hox cofactors (
To discern what target genes identified in the microarray analysis might be involved in leukemic transformation and to investigate if they are associated with Hox and Hox co-factor expression, 34 de nova AML samples collected at diagnosis from adult patients were analyzed. Complete karyotype and FLT3-ITD status was known for all subjects and represented FAB subclass M0-M5 morphologically. Six patients had favorable, 19 had intermediate and 9 had unfavorable cytogenetics (
| Patient | Cytogenetics | FLT3 | FAB | Marrow blasts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 | favorable | ITD+ | AML M3 | 50% | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 2.0 | 1.1 | 2.0 | 22.9 | 0.3 | 0.3 | 0.0 | 0.4 | 0.8 |
| 2 | favorable | Normal | AML M4 | 22% | 0.8 | 0.0 | 0.0 | 3.4 | 0.0 | 0.9 | 2.0 | 1.5 | 13.6 | 0.1 | 0.0 | 0.0 | 12.6 | 1.8 |
| 3 | favorable | Normal | AML M3 | unknown | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | 0.6 | 0.1 | 1.1 | 2.8 | 0.2 | 0.3 | 0.9 | 0.1 | 0.4 |
| 4 | favorable | Normal | AML M3 | 16% | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.6 | 22.7 | 0.2 | 0.0 | 0.0 | 0.0 | 0.6 |
| 5 | favorable | ITD+ | AML M3 | 11% | 0.3 | 0.0 | 0.0 | 0.2 | 0.1 | 0.2 | 0.2 | 1.6 | 29.5 | 0.5 | 0.5 | 0.4 | 0.4 | 1.3 |
| 6 | favorable | Normal | AML M2 | 22% | 0.3 | 0.0 | 0.0 | 0.1 | 0.0 | 0.7 | 0.7 | 1.0 | 9.8 | 0.3 | 0.0 | 0.4 | 0.6 | 0.2 |
| 7 | intermediate | Normal | AML M4 | unknown | 4.4 | 17.4 | 5.5 | 1.9 | 0.3 | 0.8 | 4.9 | 2.5 | 11.1 | 0.6 | 1.7 | 0.2 | 8.3 | 1.8 |
| 8 | intermediate | Normal | AML M1 | unknown | 7.9 | 59.2 | 16.9 | 8.0 | 0.1 | 1.5 | 3.2 | 5.3 | 81.5 | 0.4 | 0.8 | 0.8 | 16.7 | 1.6 |
| 9 | intermediate | Normal | AML M2 | 50% | 15.6 | 81.8 | 15.9 | 20.9 | 0.0 | 0.9 | 9.0 | 0.9 | 18.0 | 0.2 | 0.2 | 0.2 | 1.1 | 0.9 |
| 10 | intermediate | ITD+ | AML M1 | 79% | 16.0 | 78.8 | 24.8 | 25.4 | 0.0 | 1.2 | 11.6 | 1.5 | 37.1 | 0.2 | 0.7 | 0.4 | 1.3 | 0.9 |
| 11 | intermediate | ITD+ | AML M2 | 30% | 1.4 | 7.8 | 3.3 | 5.6 | 0.7 | 1.6 | 1.2 | 2.2 | 10.5 | 0.4 | 1.7 | 1.2 | 9.4 | 0.7 |
| 12 | intermediate | ITD+ | AML M2 | 55% | 38.8 | 357.5 | 40.9 | 65.4 | 0.1 | 1.7 | 17.1 | 7.0 | 41.7 | 3.6 | 0.8 | 0.4 | 14.2 | 1.7 |
| 13 | intermediate | Normal | AML M1 | 87% | 1.9 | 27.7 | 13.8 | 17.1 | 0.5 | 5.4 | 2.3 | 2.0 | 39.6 | 0.1 | 1.5 | 0.1 | 0.4 | 0.6 |
| 14 | intermediate | ITD+ | AML M3 | 48% | 7.7 | 0.0 | 0.0 | 0.1 | 0.0 | 0.3 | 0.9 | 3.2 | 37.4 | 0.4 | 0.0 | 0.0 | 2.0 | 0.9 |
| 15 | intermediate | Normal | AML M2 | 38% | 26.2 | 128.1 | 30.0 | 22.6 | 0.0 | 0.7 | 12.1 | 8.1 | 50.8 | 4.2 | 0.8 | 0.4 | 5.7 | 2.6 |
| 16 | intermediate | Normal | AML M1 | 46% | 0.2 | 0.9 | 0.1 | 0.2 | 0.1 | 1.8 | 0.3 | 2.8 | 8.4 | 0.2 | 0.5 | 0.2 | 2.1 | 0.6 |
| 17 | intermediate | Normal | AML M1 | 58% | 26.1 | 92.1 | 36.6 | 61.5 | 0.3 | 0.9 | 7.7 | 1.8 | 38.2 | 0.5 | 0.8 | 2.0 | 0.4 | 0.6 |
| 18 | intermediate | ITD+ | AML M2 | 77% | 15.3 | 58.9 | 20.7 | 12.7 | 0.0 | 0.9 | 1.8 | 2.7 | 41.4 | 0.2 | 1.4 | 0.8 | 0.8 | 0.5 |
| 19 | intermediate | Normal | AML M4 | 40% | 27.7 | 120.7 | 22.2 | 25.3 | 0.0 | 1.0 | 6.5 | 1.9 | 30.1 | 0.8 | 0.0 | 0.4 | 7.8 | 2.0 |
| 20 | intermediate | Normal | AML M0 | 90% | 1.1 | 1.4 | 0.4 | 0.8 | 0.7 | 1.4 | 0.7 | 0.7 | 3.4 | 0.5 | 0.7 | 0.3 | 0.6 | 0.8 |
| 21 | intermediate | Normal | AML M1 | 70% | 1.1 | 20.0 | 2.4 | 13.0 | 0.0 | 1.5 | 0.0 | 2.8 | 59.3 | 0.4 | 0.2 | 0.4 | 3.5 | 1.4 |
| 22 | intermediate | ITD+ | AML M1 | 74% | 20.5 | 45.1 | 44.9 | 42.9 | 0.0 | 0.3 | 3.8 | 3.4 | 81.4 | 0.0 | 0.1 | 0.8 | 0.9 | 0.7 |
| 23 | intermediate | Normal | AML M1 | 59% | 0.0 | 0.6 | 0.0 | 0.1 | 0.0 | 0.9 | 1.5 | 4.1 | 55.6 | 1.2 | 0.2 | 0.1 | 1.6 | 1.4 |
| 24 | intermediate | ITD+ | AML M1 | 90% | 19.0 | 184.9 | 34.7 | 61.1 | 0.0 | 0.4 | 11.9 | 2.4 | 40.2 | 0.4 | 2.2 | 0.4 | 4.3 | 0.8 |
| 25 | intermediate | Normal | AML M1 | 63% | 15.3 | 40.9 | 21.6 | 12.0 | 0.3 | 1.6 | 2.8 | 5.6 | 55.0 | 0.9 | 0.0 | 0.6 | 9.9 | 0.8 |
| 26 | unfavorable | Normal | AML M2 | 27% | 11.9 | 96.9 | 11.3 | 5.8 | 1.2 | 2.1 | 1.8 | 4.3 | 44.3 | 0.7 | 14.7 | 0.7 | 29.2 | 1.7 |
| 27 | unfavorable | Normal | AML M5 | 74% | 1.9 | 10.3 | 2.3 | 1.0 | 0.1 | 5.3 | 5.3 | 1.8 | 34.2 | 0.5 | 1.5 | 0.3 | 17.7 | 1.9 |
| 28 | unfavorable | Normal | AML M4 | 75% | 4.2 | 37.2 | 10.4 | 10.1 | 0.0 | 0.3 | 0.8 | 0.8 | 44.7 | 0.4 | 0.9 | 1.0 | 0.1 | 0.8 |
| 29 | unfavorable | Normal | AML M5 | 20% | 7.6 | 27.8 | 7.9 | 13.6 | 0.1 | 0.7 | 4.2 | 1.4 | 12.4 | 0.5 | 0.4 | 0.1 | 5.0 | 1.3 |
| 30 | unfavorable | Normal | AML M4 | 59% | 2.4 | 0.1 | 0.0 | 7.9 | 0.1 | 0.9 | 1.6 | 3.3 | 33.1 | 0.2 | 0.0 | 0.0 | 14.8 | 1.8 |
| 31 | unfavorable | Normal | AML M2 | 64% | 11.3 | 58.1 | 14.2 | 11.3 | 0.3 | 0.3 | 6.2 | 5.9 | 35.4 | 0.9 | 0.5 | 0.7 | 9.1 | 2.0 |
| 32 | unfavorable | Normal | AML M1 | 43% | 3.8 | 12.9 | 9.0 | 6.4 | 0.4 | 5.7 | 2.8 | 7.4 | 87.3 | 1.0 | 1.7 | 2.2 | 7.5 | 1.2 |
| 33 | unfavorable | Normal | AML M1 | 85% | 11.5 | 90.2 | 28.7 | 7.2 | 0.2 | 3.2 | 0.2 | 7.3 | 118.4 | 0.7 | 5.8 | 7.3 | 8.3 | 2.1 |
| 34 | unfavorable | Normal | AML M1 | 78% | 2.7 | 18.0 | 4.5 | 4.0 | 0.1 | 3.5 | 0.3 | 2.3 | 27.5 | 0.1 | 0.4 | 0.9 | 2.8 | 1.5 |
Two of the selected genes could not be detected in the majority of the samples in either normal or leukemia bone marrow (
Spearman rank correlation analysis was done on the log ratio values obtained from the TLDA assay and calculated with the 2−ΔΔCT method (n = 34).
Among the selected possible direct target genes,
Expression of the
The expression of the
The goal of this study was to identify gene expression changes that may underlie the potent growth promoting effects of Hox on primitive hematopoietic cells. Our strategy included use of two NUP98-Hox fusions with strong overlapping functional effects versus a functionally “dead” mutant form coupled with analysis of early induced gene expression changes in a HSC/progenitor cell enriched fractions. Key results included the identification of a limited number of induced genes mainly involved in cell development, cell proliferation and signal transduction, consistent with the potent effects of these fusions on promoting primitive hematopoietic cell expansion and differentiation block
Importantly, several of the suggested target genes reported herein overlap with those recently published by the study of Chung et al., in which human CD34+ cord blood was used to investigate the effects induced by
The finding of homeodomain dependent induction of
Calvo et al. have reported that NUP98-HOXA9 enforce strong transcription of endogenous
Finally, the gene array results also indicated that the NUP98-Hox genes act principally as strong transcriptional activators. Importantly, the set of genes that showed overlap between ND13 and NA10 were all induced genes suggesting that gene transcription activation rather then repression is the key to their functional effects on primitive hematopoietic cells. Interestingly, in the study by Ghannam et al. where HOXA9 or NUP98-HOXA9 were expressed in myeloid cell lines, the majority of the genes showed predominant induced expression
In summary this study identify gene expression changes that involve several different biological processes important for HSC self-renewal and proliferation and point to several interesting genes suggesting that NUP98-Hox fusions target multiple mechanisms that could potentially explain how they both transform and induce expansion of HSCs, which in turn may lead to leukemia. The next step in our investigation will be to elucidate their relative role in these processes in animal models for HSC expansion and for transforming activity. These results will also be of great help in ongoing efforts for genome wide analysis of Hox binding sites and for investigating direct binding of Hox and Hox co-factors to regulator sequences.
The authors thank Susanna Chan and Patty Rosten for valuable technical assistance and Jaswinder Khattra and Allen Delaney for valuable discussions on gene array analysis.